Trial Profile

Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immune globulin (Primary)
Indications Necrosis; Soft tissue infections
Focus Therapeutic Use
Acronyms INSTINCT

Most Recent Events

17 Jun 2021 Results (n=100) of post-hoc analysis assessing the effect of IVIG on various inflammatory cytokines up to day 3 after randomization in patients with soft-tissue infection, published in the Acta Anaesthesiologica Scandinavica.
29 Sep 2016 Status changed from active, no longer recruiting to completed.
02 Mar 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com